Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 18/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 18/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343962 | 0.81 | PDE3B (0.68) | PDE3BPDE3APDE4D | |
| SCHEMBL7340299 | 0.80 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL1386597 | 0.78 | PDE3A (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7343071 | 0.78 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7341201 | 0.74 | PDE3B (0.83) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7349060 | 0.74 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7343361 | 0.73 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL11322663 | 0.68 | PDE3B (0.69) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL20278399 | 0.67 | PDE3B (0.52) | PDE3BPDE3APDE4D | |
| SCHEMBL10267004 | 0.67 | PDE3B (0.52) | PDE3BPDE3APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | claimed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | claimed |
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | PDE3B 937/4885PDE3A 1060/4885PDE4A 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.